Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event
November 20 2017 - 8:30AM
Cellectar Biosciences (Nasdaq:CLRB), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of drugs for the treatment of cancer, today
announced that it will be presenting at the 10th Annual LD Micro
Main Event on Tuesday, December 5th at 8:30 AM PT/11:30 AM ET.
Jim Caruso, president and CEO of Cellectar, will present the
company and meet with investors. The company’s presentation will
also be webcast at http://wsw.com/webcast/ldmicro13/clrb/, and
will be posted on the company’s website following the
conference. The LD Micro Main Event will be held at the Luxe
Sunset Bel Air Hotel in Los Angeles.
About Cellectar Biosciences, Inc. Cellectar
Biosciences (Nasdaq:CLRB) is developing phospholipid drug
conjugates (PDCs) designed to provide cancer targeted delivery of
diverse oncologic payloads to a broad range of cancers and cancer
stem cells. Cellectar's PDC platform is based on the
company's proprietary phospholipid ether analogs. These novel
small-molecules have demonstrated highly selective uptake and
retention in a broad range of cancers, even sites of
metastases. The company's lead therapeutic PDC, CLR 131,
utilizes iodine-131, a cytotoxic radioisotope, as its
payload. CLR 131 has been designated as an orphan drug by the
US FDA and is currently being evaluated in a Phase 1 clinical study
in patients with relapsed or refractory multiple myeloma and a
Phase 2 clinical study to assess efficacy in a range of B-cell
malignancies. The company is also developing
proprietary PDCs for targeted delivery of chemotherapeutics and has
several preclinical stage product candidates, and plans to expand
its PDC chemotherapeutic pipeline through both in-house and
collaborative R&D efforts. For more information please
visit www.cellectar.com.
About LD MicroLD Micro was founded in 2006 with
the sole purpose of being an independent resource in the microcap
space. What started out as a newsletter highlighting unique
companies has transformed into an event platform hosting several
influential conferences annually (Invitational, Summit, and Main
Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
This news release contains forward-looking statements. You
can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among
others, uncertainties related to the ability to raise additional
capital, uncertainties related to the ability to attract and retain
partners for our technologies, the identification of lead
compounds, the successful preclinical development thereof, the
completion of clinical trials, the FDA review process and other
government regulation, our pharmaceutical collaborators' ability to
successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and
third-party reimbursement. A complete description of risks
and uncertainties related to our business is contained in our
periodic reports filed with the Securities and Exchange Commission
including our Form 10-K for the year ended December 31,
2016. These forward-looking statements are made only as of
the date hereof, and we disclaim any obligation to update any such
forward-looking statements.
CONTACT: Jules Abraham JQA Partners, Inc. 917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
From Apr 2023 to Apr 2024